Oral Diabetes Drugs Enhance Insulin Pump Therapy for Type 2 Patients

Managing Type 2 Diabetes (T2D) often requires intensive insulin therapy, with insulin pumps offering precise glucose control and improved quality of life. However, many patients still struggle with achieving optimal glycemic targets and minimizing insulin dosage. This study addresses the crucial question of how different classes of oral antidiabetic drugs (OADs) can synergistically improve outcomes when combined with insulin pump intensive therapy in T2D patients.

The study revealed significant improvements across several metrics when OADs were added to insulin pump therapy. The SGLT2 inhibitor group showed the most pronounced benefits, achieving a 1.1% reduction in HbA1c from baseline, compared to 0.7% in the metformin group, 0.5% in the sulfonylurea group, and 0.6% in the DPP-4 inhibitor group (p<0.001 for SGLT2 vs. all others). Insulin requirements were also notably reduced; the SGLT2 inhibitor group experienced a 28% decrease in total daily insulin dose, while the metformin group saw a 15% reduction (p<0.01). The SGLT2 inhibitor group demonstrated a 2.8 kg average weight loss and a 35% lower incidence of severe hypoglycemic events compared to the sulfonylurea group. The DPP-4 inhibitor group also showed a 20% reduction in hypoglycemia compared to sulfonylurea, with minimal weight change. Overall, combination therapy significantly improved glycemic control and reduced insulin burden.